Amgen (AMGN) Deferred Taxes (2013 - 2026)
Amgen (AMGN) posted quarterly Deferred Taxes of -$176.0 million for Q1 2026, up 29.6% year-over-year from -$135.8 million in Q1 2025, and down 826.32% on a QoQ basis from -$19.0 million in Q4 2025.
Amgen (AMGN) Deferred Taxes (2013 - 2026) Analysis & Trends
Amgen (AMGN) has reported Deferred Taxes for 14 consecutive years, with -$176.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Deferred Taxes rose 29.6% year-over-year to -$176.0 million; the TTM figure through Mar 2026 stood at -$647.0 million (up 39.93% YoY), while the FY2025 annual figure was -$721.0 million, up 41.29% from the prior year.
- Deferred Taxes came in at -$176.0 million for Q1 2026 at Amgen, down from -$19.0 million in the prior quarter.
- The five-year high for Deferred Taxes was -$19.0 million in Q4 2025, with the low at -$623.0 million in Q4 2023.
- Average Deferred Taxes over 5 years is -$270.4 million, with a median of -$263.0 million recorded in 2022.
- Across the five-year window, Deferred Taxes plunged 718.37% in 2024 and surged 94.31% in 2025, its largest moves.
- Year by year, Deferred Taxes stood at -$351.0 million in 2022, then plunged by 77.49% to -$623.0 million in 2023, then jumped by 46.39% to -$334.0 million in 2024, then soared by 94.31% to -$19.0 million in 2025, then sank by 826.32% to -$176.0 million in 2026.
- According to Business Quant data, Deferred Taxes over the past three periods registered -$176.0 million, -$19.0 million, and -$30.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.48 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 159.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 137.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -315.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -176.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 179.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -176.00 Mn |
| Dec 31, 2025 | -19.00 Mn |
| Sep 30, 2025 | -30.00 Mn |
| Jun 30, 2025 | -422.00 Mn |
| Mar 31, 2025 | -250.00 Mn |
| Dec 31, 2024 | -334.00 Mn |
| Sep 30, 2024 | -110.00 Mn |
| Jun 30, 2024 | -383.00 Mn |
| Mar 31, 2024 | -401.00 Mn |
| Dec 31, 2023 | -623.00 Mn |
| Sep 30, 2023 | -447.00 Mn |
| Jun 30, 2023 | -154.00 Mn |
| Mar 31, 2023 | -49.00 Mn |
| Dec 31, 2022 | -351.00 Mn |
| Sep 30, 2022 | -333.00 Mn |
| Jun 30, 2022 | -263.00 Mn |
| Mar 31, 2022 | -251.00 Mn |
| Dec 31, 2021 | -189.00 Mn |
| Sep 30, 2021 | -127.00 Mn |
| Jun 30, 2021 | -46.00 Mn |